Disease areas

Diagnostic and prognostic biomarkers for ATTRv amyloidosis

Protein biomarker discovery with Olink identifies a key protein for a rare, progressively debilitating neurological disease that could be a biomarker for diagnosis, prognosis and drug response.

Systems-level immunomonitoring of severe COVID-19

A longitudinal, systems-level approach characterizes cellular and protein immune responses in severe COVID-19, and during the recovery phase following severe disease.

Protein biomarkers of COVID-19 pathophysiology (Radboud UMC)

A team from the Netherlands used targeted proteomics to find inflammatory and other biomarkers that characterize COVID-19 and the severity of the disease.

A rare but severe complication in children with COVID-19

A study by Petter Brodin's group at the Karolinska Institute sheds new light on Inflammatory Syndrome in Children (MIS-C). The results were published in Cell.

Longitudinal COVID-19 proteomics study from MGH

Olink is immensely proud of our contribution to one of the largest longitudinal COVID-19 studies together with the prestigious Massachusetts General Hospital (MGH).

Immunotherapy

Immunotherapy is a type of treatment that harnesses the power of our own immune system to treat cancer. In a last decade, cancer immunotherapy become a foundation for cancer treatment approved for more than a dozen types of cancer, but it comes with its own challenge as not all cancer immunotherapies work for all patients.

Olink for Neurology studies

The inaccessibility of the brain and the relative scarcity of definitive physical parameters for clinical evaluation represent major challenges when it comes to neurological conditions such as neurodegenerative diseases and chronic pain.